Literature DB >> 1718087

In vivo neutralization of duck hepatitis B virus by antibodies specific to the N-terminal portion of pre-S protein.

V Lambert1, S Chassot, A Kay, C Trepo, L Cova.   

Abstract

The neutralization of duck hepatitis B virus (DHBV) infection using antibodies directed against the N-terminal portion of the large surface protein was examined in vitro and in vivo. We demonstrate here that a monoclonal antibody, directed against an epitope mapped between aa 77 and aa 100 on the DHBV pre-S, exerts a similar neutralizing activity (77%) both in vivo and in vitro. Furthermore, we have found that a polyclonal antiserum raised against the bacterially expressed 131 first amino acids of the DHBV pre-S region abolished the infectivity of DHBV in ducklings. Therefore, antibodies against a peptide representing most of the DHBV pre-S region (1-131) or a monoclonal antibody specific to an epitope within this region neutralizes in vivo DHBV infectivity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718087     DOI: 10.1016/0042-6822(91)90796-e

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

Review 1.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

2.  Selective inhibition of the duck hepatitis B virus by a new class of tetraazamacrocycles.

Authors:  O Hantz; C Borel; C Trabaud; F Zoulim; J Dessolin; M Camplo; P Vlieghe; M Bouygues; C Trepo; J L Kraus
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

3.  Residues critical for duck hepatitis B virus neutralization are involved in host cell interaction.

Authors:  C Sunyach; C Rollier; M Robaczewska; C Borel; L Barraud; A Kay; C Trépo; H Will; L Cova
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

4.  Characterization of the antiviral effect of 2',3'-dideoxy-2', 3'-didehydro-beta-L-5-fluorocytidine in the duck hepatitis B virus infection model.

Authors:  F Le Guerhier; C Pichoud; S Guerret; M Chevallier; C Jamard; O Hantz; X Y Li; S H Chen; I King; C Trépo; Y C Cheng; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

5.  Inhibitory effect of 2'-fluoro-5-methyl-beta-L-arabinofuranosyl-uracil on duck hepatitis B virus replication.

Authors:  S Aguesse-Germon; S H Liu; M Chevallier; C Pichoud; C Jamard; C Borel; C K Chu; C Trépo; Y C Cheng; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

6.  2',3'-dideoxy-beta-L-5-fluorocytidine inhibits duck hepatitis B virus reverse transcription and suppresses viral DNA synthesis in hepatocytes, both in vitro and in vivo.

Authors:  F Zoulim; E Dannaoui; C Borel; O Hantz; T S Lin; S H Liu; C Trépo; Y C Cheng
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

7.  Identification of antigenic regions of duck hepatitis B virus core protein with antibodies elicited by DNA immunization and chronic infection.

Authors:  A Thermet; M Robaczewska; C Rollier; O Hantz; C Trepo; G Deleage; L Cova
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.